- Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)Zhang, Feng; Bai, Yuxian; Fang, Weijia; Meng, Zhiqiang; Xiong, Jianping; Guo, Yabing; Zhang, Tao; Zhang, Jingdong; Ying, Jieer; Chen, Zhendong; Ren, Zhenggang; Chen, Yajin; Hao, Chunyi; Yang, Liu; Wang, Jun; Zhang, Juan; Yu, Fan; Fei, Cong; Wu, Xikun; Qin, ShukuiASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 3
- Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)Chen, Zhendong; Bai, Yuxian; Zhang, Tao; Ying, Jieer; Lin, Xiaoyan; Yang, Liu; Wang, Jun; Zhang, Juan; Yu, Fan; Fei, Cong; Huang, Ruiqi; Li, JinASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 1
- Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)Zhou, Q.; Yu, X.; Gao, B.; Ma, Z.; Chu, Q.; Huang, D.; Zhao, J.; Day, D.; Body, A. L.; Pan, H.; Cui, J.; Li, H.; Sun, J.; Zhang, J.; Fei, C.; Wu, Y-L.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.
会议论文
Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/ GEJC)
10阅读
